期刊文献+

环孢素治疗伴有8号染色体三体骨髓增生异常综合征的疗效分析

Efficacy analysis of cyclosporine in treatment of trisomy 8 myelodysplastic syndrome
原文传递
导出
摘要 骨髓增生异常综合征(MDS)是一类异质性造血干细胞克隆性疾病,其治疗策略主要依据国际预后积分系统(IPSS),结合患者年龄、体能状况、疾病进展程度等因素评价。对于大多数病程平稳、以难治性血细胞减少为主要表现的中低危MDS患者,治疗常以升高患者血细胞计数和改善患者生活质量为主。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第1期61-62,共2页 Chinese Journal of Hematology
基金 国家自然科学基金(81000921)
  • 相关文献

参考文献8

  • 1Valent P,Horny HP,Bennett JM. Def'mitions and standards in the diagnosis and treatment of the myelodysplastic syndromes:Consensus statements and report from a working conference[J].Leukemia Research,2007,(06):727-736.
  • 2Cheson BD,Greenberg PL,Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J].Blood,2006,(02):419-425.
  • 3邱镜滢,赖悦云,柴晔,张艳,师岩,何琦,党辉,陆道培.306例骨髓增生异常综合征染色体核型的研究[J].中国实验血液学杂志,2004,12(4):455-459. 被引量:32
  • 4曲士强,刘旭平,徐泽锋,张悦,秦铁军,张天佼,崔蕊,郝玉书,肖志坚.不同细胞遗传学预后分组对原发性骨髓增生异常综合征患者预后意义的研究[J].中华血液学杂志,2011,32(12):819-824. 被引量:13
  • 5Chen G,Zeng W,Miyazato A. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities[J].Blood,2004,(13):4210-4218.
  • 6Sloand EM,Kim S,Fuhrer M. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8hematopoietic cells but not in cells with other cytogenetic abnormalities[J].Blood,2002,(13):4427-4432.
  • 7Sloand EM,Mainwaring L,Fuhrer M. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphoeytes in patients with trisomy 8 myelodysplastic syndrome[J].Blood,2005,(03):841-851.
  • 8Galili N,Cemy J,Raza A. Current treatment options:impact of cytogenetics on the course of myelodysplasia[J].Current Treatment Options in Oncology,2007,(02):117-128.

二级参考文献15

  • 1薛永权.伴有8;21染色体易位的骨髓增生异常综合征的新评价[J].国外医学(输血及血液学分册),1997,20(2):105-107. 被引量:1
  • 2Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89:2079-2088.
  • 3Haase D, Germing U, Schanz J, et al. New insights into the prog- nostic impact of the karyotype in MDS and correlation with sub- types: evidence from a core dataset of 2124 patients. Blood, 2007, 110: 4385-4395.
  • 4Schanz J, Tuchler H, Sole F, et al. Proposal of a new, compre- hensive cytogenetic scoring system for primary MDS. Haematologi- ca, 2010, 95 Suppl 2: Abstract 535.
  • 5Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System ( IPSS-R), developed by the Interna- tional Prognostic Working Group for Prognosis in MDS ( IWG- PM). Leuk Res, 2011, 35 Suppl 1: Abstract 14.
  • 6Chun K, Hagemeijer A, Iqbal A, et al. Implementation of stand- ardized international karyotype scoring practices is needed to pro- vide uniform and systematic evaluation for patients with myelodys- plastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res, 2010, 34: 160- 165.
  • 7Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the rnyelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res, 2007, 31 : 727-736.
  • 8Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol, 2008, 87: 515-526.
  • 9Schanz J, Steidl C, Fonatsch C, et al. Coalesced muhicentric analysis of 2,351 patients with myelodysplastic syndromes indi- cates an underestimation of poor-risk cytogenetics of myelodysplas- tic syndromes in the International Prognostic Scoring System. J Clin Oncol, 2011,29 : 1963-1970.
  • 10Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 2005, 90: 1168-1178.

共引文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部